Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02939352 · ClinicalTrials.gov registry record · Early Phase 1
The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues
A Early Phase 1 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 49
- Enrollment target
NCT02939352: Completed Early Phase 1 study, sponsored by Medical University of South Carolina.
NCT02939352 is a Early Phase 1 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 49 participants, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02939352, a Early Phase 1 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
High relapse rates among substance dependent individuals are likely due to a combination of factors that involve limbic circuits in the brain involved in craving, including vulnerability to salient cues. Emerging data suggests that non-invasive, targeted brain stimulation may be able to modulate activity in these circuits and decrease craving. The primary goal of this pilot study is to determine the extent to which a single session of continuous theta burst stimulation to the medial prefrontal cortex can attenuate limbic circuitry involved in craving among cocaine users and alcohol users. This will be tested through a double-blind,sham-controlled brain stimulation and brain imaging study in a cohort of polysubstance abusers and alcohol users.
Interventions
- DEVICE Real continuous Theta Burst Stimulation
- DEVICE Sham continuous Theta Burst Stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-12 |
| Phase | Early Phase 1 |
What the finished NCT02939352 record still lists
NCT02939352 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Real continuous Theta Burst Stimulation is the first listed.
NCT02939352 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02939352 about?
NCT02939352 is a clinical study titled "The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues". High relapse rates among substance dependent individuals are likely due to a combination of factors that involve limbic circuits in the brain involved in craving, including vulnerability to salient cues. Emerging data suggests that non-invasive, targeted brain stimulation may be able to modulate act...
What is the current status of trial NCT02939352?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 49 participants. The study started on 2014-09. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02939352?
The interventions under investigation include: Real continuous Theta Burst Stimulation (DEVICE), Sham continuous Theta Burst Stimulation (DEVICE).
Who is sponsoring clinical trial NCT02939352?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02939352's enrollment target sits among peer trials
49 534th of 2000 higher than 1,461 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia